Last reviewed · How we verify
Personalized Neoantigen Peptide Vaccine
Personalized Neoantigen Peptide Vaccine is a Biologic drug developed by Seqker Biosciences, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Personalized Neoantigen Peptide Vaccine |
|---|---|
| Sponsor | Seqker Biosciences, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (PHASE1)
- Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (PHASE1)
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (PHASE1)
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (PHASE1)
- Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients (PHASE1)
- NeoVax Plus Ipilimumab in Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Personalized Neoantigen Peptide Vaccine CI brief — competitive landscape report
- Personalized Neoantigen Peptide Vaccine updates RSS · CI watch RSS
- Seqker Biosciences, Inc. portfolio CI
Frequently asked questions about Personalized Neoantigen Peptide Vaccine
What is Personalized Neoantigen Peptide Vaccine?
Personalized Neoantigen Peptide Vaccine is a Biologic drug developed by Seqker Biosciences, Inc..
Who makes Personalized Neoantigen Peptide Vaccine?
Personalized Neoantigen Peptide Vaccine is developed by Seqker Biosciences, Inc. (see full Seqker Biosciences, Inc. pipeline at /company/seqker-biosciences-inc).
What development phase is Personalized Neoantigen Peptide Vaccine in?
Personalized Neoantigen Peptide Vaccine is in Phase 1.